Evaluation for oral use of Ursodeoxycholyl Lysophosphatidylethanolamide (UDCA-LPE): Effective resorption of sodium salt UDCA-LPE
W Chamulitrat, H Gan-Schreier, J Wang, W Xu, N Katava, S Tuma, A Pathil-Warth, W Stremmel · Zeitschrift für Gastroenterologie · 2013 · Heft 01
Bibliografische Angaben
Zusammenfassung
Introduction: UDCA-LPE when administered intraperitoneally (i.p.) is cytoprotective in inhibiting liver injury and inflammation in fulminant LPS-induced hepatitis and ameliorating steatosis, inflammation and fibrosis in mouse models of non-alcoholic steatosis hepatitis (NASH). We previously showed that i.p. injected UDCA-LPE was hydrolyzed back to UDCA and LPE. It is questionable whether UDCA-LPE could be an orally active drug. Methods: C57/BL6 mice were fed with high fat diet (HFD, 35% w/w) for 6 months or fed with HFD for 3 months and oral gavaged with 30mg/kg UDCA-LPE twice a week for further 3 months on HFD.…
